ArticleJournal of clinical microbiology2015
Performance of the molecular Alere I influenza A&B test compared to that of the xpert flu A/B assay.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.Clinical microbiology reviews · 2019Guideline
- Diagnostic accuracy of rapid integrated molecular testing for major respiratory viral infections: a systematic review and meta-analysis.Frontiers in medicine · 2026Article
- Near-digital amplification in paper improves sensitivity and speed in biplexed reactions.Scientific reports · 2022Article
- Developments in integrating nucleic acid isothermal amplification and detection systems for point-of-care diagnostics.Biosensors & bioelectronics · 2020Review
- Improved performances of the second generation of the ID NOW influenza A&B 2® and comparison with the GeneXpert®.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- The impact of point-of-care testing for influenza A and B on patient flow and management in a medical assessment unit of a general hospital.BMC research notes · 2020Article
- Comparison of the ID Now Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid Amplification Tests for Influenza A/B Virus Detection in Children.Journal of clinical microbiology · 2020Article
- Advances in Directly Amplifying Nucleic Acids from Complex Samples.Biosensors · 2019Review
- Cost-Effective Respiratory Virus Testing.Journal of clinical microbiology · 2019Review
- Amplification chemistries in clinical virology.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2019Review
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children.Journal of clinical microbiology · 2018Article
- Are Rapid Influenza Antigen Tests Still Clinically Useful in Today's Molecular Diagnostics World?Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2018Article
- Paying for Point-of-Care Nucleic Acid Amplification Tests: a Micro-Comic Strip.Journal of clinical microbiology · 2018Article
- Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test.Expert review of molecular diagnostics · 2018Article
- Accurate PCR Detection of Influenza A/B and Respiratory Syncytial Viruses by Use of Cepheid Xpert Flu+RSV Xpress Assay in Point-of-Care Settings: Comparison to Prodesse ProFlu.Journal of clinical microbiology · 2018Article
- Article
- Point-of-care diagnostics for respiratory viral infections.Expert review of molecular diagnostics · 2018Review
- Right-Sizing Technology in the Era of Consumer-Driven Health Care.Clinical microbiology newsletter · 2017Article
- Multicenter Clinical Evaluation of the Luminex Aries Flu A/B & RSV Assay for Pediatric and Adult Respiratory Tract Specimens.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the performance of rapid molecular point-of-care use platforms for diagnosis of influenza are lacking. We validated nasopharyngeal (NP) flocked specimens in universal transport medium (UTM) and evaluated the clinical sensitivity and specificity of the Alere i influenza A&B test compared to those of the Xpert flu A/B assay. The Alere i influenza A&B test had an overall sensitivity and specificity of 93.8% and 62.5% for influenza A, respectively, and of 91.8% and 53.6% for influenza B, respectively. The poor specificity was due to influenza virus samples determined positive for both type A and B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.